US2018098983A1PendingUtilityA1

Certain chemical entities, compositions and methods

67
Assignee: INTELLIKINE LLCPriority: Jan 4, 2008Filed: May 18, 2017Published: Apr 12, 2018
Est. expiryJan 4, 2028(~1.5 yrs left)· nominal 20-yr term from priority
Inventors:Pingda RenYi LiuTroy Edward WilsonLiansheng LiKatrina ChanChristian Rommel
A61P 3/10A61P 37/02A61P 37/08A61P 37/00A61P 7/00A61P 35/02A61P 35/00A61P 7/02A61P 37/06A61P 5/00A61P 43/00A61P 9/00A61P 3/00A61P 25/00A61P 29/00A61P 27/00A61P 1/00A61P 13/00A61P 19/02A61P 19/00A61P 11/06A61P 17/00A61P 11/00A61P 19/08A61P 17/06A61N 2005/109A61K 39/39558A61N 5/10C07D 473/34A61K 31/131A61K 31/506A61K 45/06C07D 487/04A61N 5/1007A61K 31/196A61K 31/52A61K 31/5377A61K 31/4725A61K 39/3955Y02P20/55C07D 473/38C07D 473/04C07D 401/06A61K 31/4985Y02A50/30
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein.

Claims

exact text as granted — not AI-modified
1 - 20 . (canceled). 
     
     
         21 . A method of treating cancer in a subject, comprising administering to the subject an effective amount of a compound of formula: 
       
         
           
           
               
               
           
         
         wherein the cancer is leukemia or lymphoma. 
       
     
     
         22 . The method of  claim 21 , wherein the cancer is leukemia. 
     
     
         23 . The method of  claim 21 , wherein the cancer is chronic lymphocytic leukemia (CLL). 
     
     
         24 . The method of  claim 21 , wherein the cancer is acute lymphocytic leukemia. 
     
     
         25 . The method of  claim 21 , wherein the cancer is acute myelogenous leukemia (AML). 
     
     
         26 . The method of  claim 21 , wherein the cancer is chronic myelogenous leukemia (CML). 
     
     
         27 . The method of  claim 21 , wherein the cancer is hairy cell leukemia. 
     
     
         28 . The method of  claim 21 , wherein the cancer is lymphoma. 
     
     
         29 . The method of  claim 21 , wherein the cancer is non-Hodgkin lymphoma. 
     
     
         30 . The method of  claim 21 , wherein the cancer is diffuse large B-cell lymphoma. 
     
     
         31 . The method of  claim 21 , wherein the cancer is adult T-cell lymphoma. 
     
     
         32 . The method of  claim 21 , wherein the cancer is Hodgkin disease. 
     
     
         33 . The method of  claim 21 , wherein the cancer is small non-cleaved cell lymphoma. 
     
     
         34 . The method of  claim 21 , wherein the cancer is B-cell immunoblastic lymphoma. 
     
     
         35 . The method of  claim 21 , further comprising administering to the subject a second therapeutic agent, wherein the second therapeutic agent is bortezomib. 
     
     
         36 . The method of  claim 28 , further comprising administering to the subject a second therapeutic agent, wherein the second therapeutic agent is bortezomib. 
     
     
         37 . The method of  claim 29 , further comprising administering to the subject a second therapeutic agent, wherein the second therapeutic agent is bortezomib.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.